ArticleBiometrics2017
A subgroup cluster-based Bayesian adaptive design for precision medicine.
Article in Biometrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity.Journal of the Royal Statistical Society. Series C, Applied statistics · 2025Article
- A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine.Statistics in medicine · 2025Article
- Latest Developments in "Adaptive Enrichment" Clinical Trial Designs in Oncology.Therapeutic innovation & regulatory science · 2024Review
- Machine learning identifies prognostic subtypes of the tumor microenvironment of NSCLC.Scientific reports · 2024Article
- Bayesian Sequential Design for Identifying and Ranking Effective Patient Subgroups in Precision Medicine in the Case of Counting Outcome Data with Inflated Zeros.Journal of personalized medicine · 2023Article
- Precision oncology: a review to assess interpretability in several explainable methods.Briefings in bioinformatics · 2023Review
- Innovative trial design in precision oncology.Seminars in cancer biology · 2022Review
- A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies.Journal of personalized medicine · 2022Review
- Enrichment Bayesian design for randomized clinical trials using categorical biomarkers and a binary outcome.BMC medical research methodology · 2022Article
- Variance prior specification for a basket trial design using Bayesian hierarchical modeling.Clinical trials (London, England) · 2019Article
- Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Designs.JCO precision oncology · 2019Review
- Design and implementation of pragmatic clinical trials using the electronic medical record and an adaptive design.JAMIA open · 2018Article
- Specifying the True- and False-Positive Rates in Basket Trials.JCO precision oncology · 2017Article
- Personalized or Precision Medicine? The Example of Cystic Fibrosis.Frontiers in pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In precision medicine, a patient is treated with targeted therapies that are predicted to be effective based on the patient's baseline characteristics such as biomarker profiles. Oftentimes, patient subgroups are unknown and must be learned through inference using observed data. We present SCUBA, a Subgroup ClUster-based Bayesian Adaptive design aiming to fulfill two simultaneous goals in a clinical trial, 1) to treatments enrich the allocation of each subgroup of patients to their precision and desirable treatments and 2) to report multiple subgroup-treatment pairs (STPs). Using random partitions and semiparametric Bayesian models, SCUBA provides coherent and probabilistic assessment of potential patient subgroups and their associated targeted therapies. Each STP can then be used for future confirmatory studies for regulatory approval. Through extensive simulation studies, we present an application of SCUBA to an innovative clinical trial in gastroesphogeal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.